Ipsen (IPN) Q3 2026 TU earnings summary

Executive summary

• Q3 sales reached €1,173.9m, up 26.7% at CER; YTD sales were €3,364.2m, up 24.6% at CER and 23.0% as reported.

• Strong core-portfolio growth supported upgraded FY 2026 sales-growth and core operating-margin guidance.

• Late-stage pipeline and recent acquisitions expanded potential catalysts across Oncology, Rare Disease and Neuroscience.

Financial highlights

• Q3 Core Portfolio sales were €793m, up 23.3%; YTD sales were €2,297m, up 24.2%.

• YTD therapy-area sales: Oncology €2,196.9m, up 16.3%; Rare Disease €498.2m, up 100.1%; Neuroscience €669.1m, up 18.8% at CER.

• YTD medicine sales included Somatuline €1.067B, up 25.5%; Cabometyx €523m, up 15.6%; Iqirvo €283m, up 170.8%; and Bylvay €189m, up 43.8%.

• Currency reduced YTD sales growth by 1.6 percentage points.

Outlook and guidance

• FY 2026 sales-growth guidance rose to ~23.0% at CER from >20.0%; core operating-margin guidance increased to ~39.0% of sales from >37.0%.

• October exchange rates imply an adverse currency impact of ~0.5% on total sales; guidance assumes Somatuline growth despite expected generic lanreotide entry in Q4.

• Management expects 2027 margin to decline from the exceptional 2026 level due to mix, Somatuline erosion, and launch and development investment; margins are expected to remain significant in the midterm.

• Iqirvo’s sales ambition increased from >€500m to €1B, with lower-ALP patients representing a significant expansion opportunity.